The aggressive biological behavior of invasive and metastatic cancer is considered to be the most insidious and life-threatening aspect for breast cancer patients. It is mostly the result of changes in many molecular characteristics of tumor cells, including alterations in the mechanisms controlling cell growth and proliferation.
Aim
The aim of this retrospective study was to identify predictors of aggressive biological behavior and metastatic potential in breast carcinoma among a number of intrinsic bio-markers of tumor cells such as steroid receptors and oncogene and tumor suppressor gene products.
Methods
Routine formalin-fixed, paraffin-embedded tumor samples were used and sections were stained immunohistochemically with the DAKO Strept ABC method to determine the expression of estrogen receptors (ER), progesterone receptors (PgR), HER-2/neu, bcl-2, Ki-67, p53 and nm23 in 192 consecutive breast carcinoma patients. The results of the quantitative immunohistochemical assays were correlated with clinical and histological data such as patient age, overall survival, tumor size, axillary lymph node status, hystological type, tumor grade, Nottingham prognostic index (NPI) and therapeutic regimens.
Results
Univariate analysis revealed that survival was significantly longer for patients with small tumors (P = 0.007), lower tumor grade (P = 0.021), negative axillary lymph nodes (P = 0.002), presence of nm23 protein (P = 0.002), and for patients treated with adjuvant hormonal therapy (P = 0.010). In multivariate analysis the independent factors positively affecting survival were absence of axillary lymph node metastases (P = 0.002), nm23 expression (P = 0.009) and hormonal therapy (P = 0.050). Among patients with positive axillary nodes there was a significantly higher survival rate in patients with nm23 expression compared with nm23-negative patients (P <0.001).
Conclusion
Identification of a subset of node-positive breast cancer patients with a more favorable prognosis according to nm23 expression might be clinically useful.
LeM.G., ArriagadaR., SpielmannM., GuinebretiereJ.M., RochardF: Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer, 94: 2813–2820, 2002.
2.
LashT.L., SillimanR.A., GuadagnoliE., MorV: The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer, 89: 1739–1747, 2000.
3.
SierraA., CastellsagueX., EscobedoA., LloverasB., Garcia-RamirezM., MorenoA., FabraA: Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer. Int J Cancer, 89: 142–147, 2000.
4.
GarciaI., DietrichP.Y., AaproM., VauthierG., VadasL., EngelE: Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res, 49: 6675–6679, 1989.
5.
PintoA.E., AndreS., PereiraT., NobregaS., SoaresJ: C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol, 12: 525–533, 2001.
6.
ThikeA.A., ChngM.J., Fook-ChongS., TanPH: Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology, 33: 21–25, 2001.
7.
MichaelsonJ.S., SilversteinM., WyattJ., WeberG., MooreR., HalpernE., KopansD.B., HughesK: Predicting the survival of patients with breast carcinoma using tumor size. Cancer, 95: 713–723, 2002.
8.
MirzaA.N., MirzaN.Q., VlastosG., SingletarySE: Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg, 235: 10–26, 2002.
9.
BangS.M., HeoD.S., LeeK.H., ByunJ.H., ChangH.M., NohD.Y., ChoeK.J., BangY.J., KimS.R., KimNK: Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer, 89: 2521–2526, 2000.
10.
BerardoM.D., ElledgeR.M., de MoorC., ClarkG.M., OsborneC.K., AllredDC: bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer, 82: 1296–1302, 1998.
11.
HartveitF: Node-positive breast cancer: axillary micrometastases, their incidence and some implications. Invasion Metastasis, 16: 317–321, 1996.
12.
Bisho McGuireWL: Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst, 83: 154–155, 1991.
13.
Wang-RodriguezJ., CrossK., GallagherS., DjahanbanM., ArmstrongJ.M., WiednerN., ShapiroDH: Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol, 15: 853–861, 2002.
14.
WatataniM., InuiH., NagayamaK., ImanishiY., NishimuraK., HashimotoY., YamauchiE., HojoT., KotsumaY., YamatoM., MatsunamiN., YasutomiM: Identification of high-risk breast cancer patients from genetic changes of their tumors. Surg Today, 30: 516–522, 2000.
15.
JohnstonJ: Human genetic disorders. J NIH Res, 4: 153, 1992.
16.
BenzEJ: The molecular genetics of cancer: introduction to principles of recombinant DNA technology. Cancer, 65: 731, 1990.
17.
DracopoliN.C., HainesJ.L., KorfB.R., MoirD.T., MortonC.C., SeidmanJ.G., SmithDR (Eds): Current protocols in human genetics.John Wiley & Sons, New York, 1994.
18.
DelidesG.S., GarasG., GeorgouliG, JiortziotisD., LeccaJ., LivaT., ElemenglouJ: Intralaboratory variations in the grading of breast carcinoma. Arch Pathol Lab Med, 106: 126–128, 1982.
19.
GaspariniG., PozzaF., HarrisAL: Methodology of evaluation and potential usefulness of the new biological-related prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst, 85: 1206–1219, 1993.
20.
KinneDW: Staging and follow-up of breast cancer patients. Cancer, 67: 1196–1198, 1991.
21.
World Health Organisation: Histological typing of breast tumors. Tumori, 68: 181–198, 1982.
22.
ElstonC.W., EllisIO: The breast, 3rd ed, Churchill Livingstone, London, 1998.
23.
GaleaM.H., BlarneyR.W., ElstonC.E., EllisIO: The Nottingham prognostic index in primary breast cancer. Br Cancer Res Treat, 22: 207–219, 1992.
24.
MatsuoK., FukutomiT., Akashi-TanakaS., HasegawaT., TsudaH: Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma. Breast Cancer, 9: 127–133, 2002.
25.
IoachimE., CharchantiA., BriasoulisE., KaravasilisV., TsanouH., ArvantisD.L., AgnantisN.J., PavlidisN: Immunohistochemical expression of extracellular matrix component tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer, 38: 2362–2370, 2002.
26.
KaplanE.L., MeierP: Non-parametric estimation from incomplete observations. Am Stat Assoc J, 53: 457–481, 1958.
27.
CoxDR: Regression models and life tables. J R Stat Soc, 84: 1035–1044, 1972.
28.
DeviK.R., KuruvilaS., MusaMM: Pathological prognostic factors in breast carcinoma. Saudi Med J, 21: 372–375, 2000.
29.
CarterC.L., AllenC., HensonDE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 63: 181–186, 1989.
30.
Medina-FrancoH., UristMM: Occult breast carcinoma presenting with axillary lymph node metastases. Rev Invest Clin, 54: 204–208, 2002.
31.
MillisR.R., SpringallR.J., HanbyA.M., RyderK., FentimanIS: A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer, 88: 108–113, 2000.
32.
MenardS., ValagussaP., PilottiS., GianniL., BiganzoliE., BoracchiP., TomasicG., CasaliniP., MarubiniE., ColnaghiM.I., CascinelliN., BonadonnaG: Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol, 19: 329–335, 2001.
33.
CrombieN., RampaulR.S., PinderS.E., ElstonC.W., RobertsonJ.F., EllisIO: Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma. Br J Surg, 88: 1324–1329, 2001.
34.
KeshtgarM.R., BaumM: Axillary dissection over the years: where to from here?World J Surg, 25: 761–766, 2001.
35.
LashT.L., SillimanR.A., GuadagnoliE., MorV: The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer, 89: 1739–1747, 2000.
36.
ClarkJ., EdwardsS., JohnM., FlohrP., GordonT., MaillardK., GiddingsI., BrownC., BagherzadehA., CampbellC., ShipleyJ., WoosterR., CooperCS: Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes Cancer, 34: 104–114, 2002.
37.
HoG.H., CalvanoJ.E., BisognaM., AbouezziZ., BorgenP.I., Cordon-CardoC., van ZeeKJ: Genetic alterations of the p14ARF-hdm2-p53 regulatory pathway in breast carcinoma. Breast Cancer Res Treat, 65: 225–232, 2001.
38.
ThomsonA.M., SteelC.M., ChettyU., CarterDC: Evidence for the multistep theory of carcinogenesis in human breast carcinoma. Breast, 1: 29, 1992.
39.
BishopJM: The molecular genetics of cancer. Science, 235: 305, 1987.
40.
BishopJM: Molecular themes in oncogenesis. Cell, 64: 235, 1991.
41.
SchwabM., AmlerLC: Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer. Genes Chromosomes Cancer, 1: 181, 1990.
42.
LeeEY-HP: Tumor suppressor genes: a new era for molecular genetic studies of cancer. Breast Cancer Res Treat, 19: 3, 1991.
MonteroS., GuzmanC., VargasC., BallestinC., Cortes-FunesH., ColomerR: Prognostic value of cytosolic p53 protein in breast cancer. Tumour Biol, 22: 337–344, 2001.
45.
KymionisG.D., DimitrakakisC.E., KonstadoulakisM.M., ArzimanoglouI., LeandrosE., ChalkiadakisG., KeramopoulosA., MichalasS: Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?J Surg Res, 99: 161–168, 2001.
46.
EissaS., KhalifaA., el-GharibA., SalahN., MohamedMK: Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res, 17: 3091–3097, 1997.
47.
TravisA., PinderS.E., RobertsonJ.F., BellJ.A., WencykP., GullickW.J., NicholsonR.I., PollerD.N., BlarneyR.W., ElstonC.W., EllisIO: C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer, 74: 229–233, 1996.
48.
El-AhmadyO., El-SalahyE., MahmoudM., WahabM.A., EissaS., KhalifaA: Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up. Anticancer Res, 22: 2493–2499, 2002.
49.
ReedW., HannisdalE., BoehlerP.J., GundersenS., HostH., MarthinJ: The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14–30 years. Cancer, 88: 804–813, 2000.
50.
RaabeN.K., HagenS., HaugE., FossaaSD: Hormone receptor measurements and survival in 1335 consecutive patients with primary invasive breast carcinoma. Int J Oncol, 12: 1091–1096, 1998.
51.
GohringU.J., ScharlA., HeckelC., AhrA., CrombachG: P53 protein in 204 patients with primary breast carcinoma: immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet, 256: 139–146, 1995.
52.
KatakuraH., TanakaF., OyanagiH., MiyaharaR., YanagiharaK., OtakeY., WadaH: Clinical significance of nm23 expression in resected pathologic-stage I, non-small cell lung cancer. Ann Thorac Surg, 73: 1060–1064, 2002.
53.
NiuY., FuX., LvA., FanY., WangY: Potential markers predicting distant metastasis in axillary node-negative breast carcinoma. Int J Cancer, 98: 754–760, 2002.
54.
SauerT., FuruI., BerakiK., JebsenP.W., OrmerodE., NaessO: Nm23 protein expression in fine-needle aspirates from breast carcinoma: inverse correlation with cytologic grading, lymph node status, and ploidy. Cancer, 84: 109–114, 1998.
